Moreover, those with MDS/AML-NOS had the longest survivals (vs. MDS/AML with mutated TP53; 8.1 months for LFS, P = 0.052; 28.1 months for OS, P < 0.001) (Supplementary Fig. 12). The gene discussed is TP53; the disease is acute myeloid leukemia.